ADK and 4D4A Related Headlines
Go Back- DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants
- DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
- DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
- DIAGNOS Announces the Engagement of IBN
- DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
- DIAGNOS Appoints Dr. Ismail Ben Ayed as Chief Artificial Intelligence (AI) Scientist to Accelerate our Innovation in Healthcare
- DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025
- DIAGNOS appoints Philippe Couillard as board chairman
- DIAGNOS Strengthens Governance and Leadership with the Appointment of Philippe Couillard as Chairman of the Board of Directors
- DIAGNOS adds orthopedic surgeon to advisory board
- DIAGNOS Welcomes Dr. Pierre-Luc Charlebois to its Advisory Board
- DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025
- Validated for Global Scale: DIAGNOS Passes Annual MDSAP Audit, Solidifying the Pathway to Approvals with Health Canada & FDA
- DIAGNOS Announces Voting Results of Meeting of Shareholders
- DIAGNOS closes $100,000 private placement with convertible debentures
- DIAGNOS Announces Closing of Private Placement
- DIAGNOS raises $100,000 through private placement of convertible units
- DIAGNOS Announces Private Placement
- DIAGNOS to Extend Stock Warrants Exercise Period
- DIAGNOS Announces Extension of Stock Warrants Exercise Period
- DIAGNOS Files FDA Pre-Submission for its CARA System: Strategic Entry into the U.S. Optometry Market with Support from ORA LLC
- DIAGNOS Welcomes Veteran Optometrist Dr. Barry A. Ginsberg to its Scientific Advisory Board for the United States
ADK and 4D4A Related Press Releases
Go Back- DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants
- DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
- DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
- DIAGNOS Announces the Engagement of IBN
- DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
- DIAGNOS Appoints Dr. Ismail Ben Ayed as Chief Artificial Intelligence (AI) Scientist to Accelerate our Innovation in Healthcare
- DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025
- DIAGNOS Strengthens Governance and Leadership with the Appointment of Philippe Couillard as Chairman of the Board of Directors
- DIAGNOS Welcomes Dr. Pierre-Luc Charlebois to its Advisory Board
- DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025
- Validated for Global Scale: DIAGNOS Passes Annual MDSAP Audit, Solidifying the Pathway to Approvals with Health Canada & FDA
- DIAGNOS Announces Voting Results of Meeting of Shareholders
- DIAGNOS Announces Closing of Private Placement
- DIAGNOS Announces Private Placement
- DIAGNOS to Extend Stock Warrants Exercise Period
- DIAGNOS Announces Extension of Stock Warrants Exercise Period
- DIAGNOS Files FDA Pre-Submission for its CARA System: Strategic Entry into the U.S. Optometry Market with Support from ORA LLC
- DIAGNOS Welcomes Veteran Optometrist Dr. Barry A. Ginsberg to its Scientific Advisory Board for the United States
